Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Clinical trial NCT07747740 · RECRUITING

Trial details

NCT number: NCT07747740
Sponsor: Blokhin's Russian Cancer Research Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Muscle-Invasive Bladder Cancer BCG-Unresponsive Bladder Cancer

Start date: 2026-07-09
Primary completion: 2029-12-30
Enrollment: 228

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.